Alobresib
- Generic Name
- Alobresib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N5O2
- CAS Number
- 1637771-14-2
- Unique Ingredient Identifier
- 3QBL0BLP3D
- Background
Alobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 31
- Registration Number
- NCT02607228
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT02392611
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath